Cohen 2014.

Study name	Effects of meditation on cognitive function and quality of life
Methods	RCT
Participants	Inclusion Criteria Female breast cancer patients aged 35 to 60 years old, stage I‐III who have undergone chemotherapy (either neoadjuvant or adjuvant) 6 to 60 months prior to recruitment; who are currently undergoing hormone therapy; who report cognitive impairment since starting chemotherapy as assessed by four questions of the FACT‐Cog; able to read and speak English, Spanish or Portuguese; who are all right‐handed (for EEG analysis) and willing to travel to one of two centres for meditation and assessment. Exclusion Criteria Diagnosis of a formal thought disorder (e.g. schizophrenia) or neurological disorder known to affect cognitive function; MMSE score of 23 or less; recurrent cancer; neurological/psychological disorder that may interfere with ability to co‐operate with study procedures; factors affecting fMRI and extreme mobility issues and regular meditation practice (at least once a week for the last year). Comparators Wait‐list controls Non‐cancer controls: Women with no history of cancer or prior chemotherapy. Exclusions; taking oestrogen blockers or stimulators, extreme mobility issues or primary caretaker of a cancer patient. Country: USA
Interventions	Definition: Tibetan Sound Meditation Materials: CD and instructions for home practice Duration: Twice weekly one‐hour sessions over a 8‐week period Setting: Group‐based setting Personnel: Meditation instructor
Outcomes	Assessments at baseline and 8 weeks later at end of the intervention period Primary outcome Cognitive function Secondary outcomes Mood, fatigue, QoL, memory and concentration EEG and fMRI
Starting date	October 2013
Contact information	Lorenzo Cohen: lcohen@mdanderson.org
Notes	Specific measures not reported